International Journal of Medical Sciences

Impact factor

14 November 2018

ISSN 1449-1907 News feeds of published articles

Manuscript login | Account

open access Global reach, higher impact

Journal of Genomics in PubMed Central. Submit manuscript now...


Journal of Cancer

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)


Journal of Biomedicine


PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2008; 5(6):309-312. doi:10.7150/ijms.5.309

Research Paper

Lamivudine treatment for severe acute HBV hepatitis

Andrea Lisotti, Francesco Azzaroli, Federica Buonfiglioli, Marco Montagnani, Flavio Alessandrelli, Giuseppe Mazzella

Department of Digestive Disease and Internal Medicine, University “Alma Mater Studiorum” of Bologna, Ospedale S'Orsola-Malpighi via Massarenti 9 Bologna, Italy


Treatment for acute hepatitis B is recommended in order to reduce the risk of progression to fulminant hepatitis and the need of OLT. We report our experience on treatment with high dose lamivudine, in patients with severe acute HBV infection. The diagnosis was based on clinical and virological findings and exclusion of other known causes of liver damage. The decision to treat was based on the prolongation of INR together with increasing values of bilirubin and ALT. Four patients received Lamivudine 200 mg/daily until clearance of serum HBV-DNA and then 100 mg/daily until clearance of HBsAg and appearance of anti-HBs antibodies. One patient received 100 mg/daily because of chronic renal impairment. The median period of hospitalization was 13 days, and none of the patients had complications, related either to underlying disease or to therapy. The complete normalization of serum transaminases and bilirubin occurred on average after 5.5 weeks and 3 weeks respectively. All patients cleared serum HBV-DNA within three months, lost HBeAg and HBsAg and seroconverted to anti-HBe; four patients developed anti-HBs at a protective titre. Early antiviral treatment attenuates the clinical and biochemical impairment leading to fast healing and promoting complete recovery.

Keywords: acute HBV hepatitis, lamivudine, fulminant hepatitis, treatment, recovery

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See for full terms and conditions.
How to cite this article:
Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Alessandrelli F, Mazzella G. Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci 2008; 5(6):309-312. doi:10.7150/ijms.5.309. Available from